Microvascular responsiveness in obesity: implications for therapeutic intervention by Bagi, Zsolt et al.
  
Microvascular responsiveness in obesity - implications for therapeutic intervention 
‘Review’* 
 
1,2Zsolt Bagi, 2Attila Feher and 2James Cassuto 
 
1Department of Pharmacology, University of Oxford, UK and 2Department of Physiology, New 
York Medical College, Valhalla, New York, USA 
 
Running title: Obesity and microcirculation 
 
Correspondence: Zsolt Bagi M.D., Ph.D. 
Department of Pharmacology, University of Oxford 
Oxford, Mansfield Road, OX1 3QT, United Kingdom 
Tel: 01865 271627 
Fax: 01865 271853 
 E-mail: zsolt.bagi@pharm.ox.ac.uk 
 
 
 
 
 
                                                 
This is an Accepted Article that has been peer-reviewed and approved for 
publication in the British Journal of Pharmacology, but has yet to undergo 
copy-editing and proof correction. Please cite this article as an “Accepted 
Article”; doi: 10.1111/j.1476-5381.2011.01606.x 
   1 
 
 
 SUMMARY 
 
Obesity has detrimental effects on the microcirculation. Functional changes in 
microvascular responsiveness may increase the risk of developing cardiovascular complications 
in obese patients. Emerging evidence indicates that selective therapeutic targeting of the 
microvessels may prevent life-threatening obesity-related vascular complications, such as 
ischemic heart disease, heart failure and hypertension. It is also plausible that alterations in 
adipose tissue microcirculation contribute to the development of obesity. Therefore, targeting 
adipose tissue arterioles could represent a novel approach to reducing obesity.  This review aims 
to examine recent studies that have been focused on vasomotor dysfunction of resistance arteries 
in obese humans and animal models of obesity. Particularly, findings in coronary resistance 
arteries are contrasted to those obtained in other vascular beds. We provide examples of 
therapeutic attempts, such as use of statins, angiotensin converting enzyme inhibitors and insulin 
sensitizers to prevent obesity-related microvascular complications. We further identify some of 
the important challenges and opportunities going forward.   
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 ABBREVIATIONS 
 
 
BMI, body mass index; ACh, acetylcholine; SNP, sodium nitroprusside; NO, nitric oxide; ROS, 
reactive oxygen species; RNS, reactive nitrogen species; H2O2, hydrogen peroxide; IL, 
interleukin; TNFα, tumor necrosis factor α; MCP-1, monocyte chemotactic protein-1; EDHF, 
endothelium derived hyperpolarizing factor; KCa, Ca2+ activated potassium channel; PET, 
positron emission tomography; sGC, soluble guanylate cyclase, HIF-1α, hypoxia inducible 
factor 1α; TZD, thiazolidinedione; BH4, tetrahydrobiopterin; ACE, angiotensin converting 
enzyme; ARB, angiotensin receptor blocker; NEP, neutral endopeptidase; RAS, renin-
angiotensin system 
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 INTRODUCTION 
Morphological changes in microvessels are quite rare in obesity prior to the development of 
hyperglycaemia and type 2 diabetes mellitus. Obesity-related pathological alterations, including 
atherogenic dyslipidaemia, insulin resistance and hyperinsulinaemia impair the vasomotor 
function of arteries. It has been the view that blood flow to various organs is rarely impaired in 
obesity, unless occlusive atherosclerosis of the larger arteries develops. Throughout life organs 
receive normal or even greater than normal blood flow in uncomplicated obesity (Hall et al., 
1999). Recent studies using non-invasive imaging techniques revealed that myocardial perfusion 
and skeletal muscle blood flow are compromised in obese subjects especially when vessels are 
pharmacologically or metabolically challenged. Such abnormalities are primarily due to the 
reduced vasodilator capacity of microvessels, which in some instances represents important 
markers of cardiovascular risk or may even contribute to the pathogenesis of obesity. 
Although the importance of microvascular vasomotor dysfunction in contributing to the 
morbidity and mortality of obese patients was appreciated many years ago, no effective 
therapeutic strategies are currently available to prevent abnormalities of resistance arteries. 
Recent studies raise the prospect that therapeutically targeting the microcirculation may not only 
prevent vascular complications but via interfering with adipose tissue vascularization may reduce 
obesity. This review aims to examine studies that focus on alterations in vasodilator function of 
resistance arteries in obesity. A description is also provided about the underlying cellular 
mechanisms in endothelial, vascular smooth muscle cells and adipocytes that are believed to be 
responsible for altered microvascular responsiveness. Moreover, recent interventional studies of 
obesity are summarized, in which the primary focus was to reverse microvascular dysfunction by 
using various pharmacological treatments.  
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 Obesity and altered microvascular responsiveness – the nature of underlying mechanisms 
In humans, obesity is associated with reduced hyperemia-induced forearm blood flow 
(Hashimoto et al., 1998; Vigili de Kreutzenberg et al., 2003). Obese children already exhibit 
impaired brachial artery relaxation to hyperemic flow (Kapiotis et al., 2006). In their study 
Karpoff et al have found that mild-to-moderate obesity (body mass index, BMI: 23.9±2.6) in 
prepubertal boys without insulin resistance is associated with blunted flow-mediated dilation in 
the brachial artery (Karpoff et al., 2009). In normal weight adults an average weight gain of 4.1 
kg impaired flow-mediated dilation, which was restored to baseline when subjects shed the 
gained weight (Romero-Corral et al., 2010). These observations provide evidence that obesity, 
without any co-existing cardiovascular diseases, is associated with impaired vasomotor function 
of conduit arteries.  
Forearm resistance arteries also possess a reduced endothelium-dependent, acetylcholine 
(ACh)- and endothelium-independent, sodium nitroprusside (SNP)-induced dilations in obese 
individuals (Sivitz et al., 2007), suggesting microvascular involvement. An early study 
demonstrated that peripheral vascular resistance inversely correlate to body mass index (BMI), 
whereas elevated waist/hip ratio is associated with increased systemic vascular resistance (Jern et 
al., 1992). This example implies that visceral obesity is associated with increased total peripheral 
vascular resistance. It has been proposed that an increase in body fat mass and its visceral 
localization are responsible for the impaired vasodilation of resistance vessels (Hashimoto et al., 
1998) and consequently elevated peripheral vascular resistance in obesity (Jern et al., 1992). This 
scenario was also supported by a theoretical analysis using physiological measurements obtained 
in obese patients (Ferrannini, 1992). Thus, obesity impairs the vasomotor function of 
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 microvessels that determine peripheral resistance, but the exact mechanisms are largely unknown 
in obese patients.  
Diminished vasodilator function of resistance arteries develops in animals with experimental 
obesity, making it feasible to study the underlying pathology, which usually is very difficult to 
perform in man. In evaluating results obtained from animal models of obesity it is important to 
bear in mind that similar to humans, experimental obesity is associated with co-morbid 
conditions, such as elevated systemic blood pressure. Also, it is important to note that even in the 
absence of fasting hyperglycemia, animals with experimental insulin resistance develop elevated 
postprandial glucose levels. Thus, the pathological role of high blood pressure and transient 
hyperglycaemia should be taken into account when evaluating the impact of obesity in these 
animal models. Moreover, in commonly used animal models, obesity develops on the basis of 
mutations in the leptin gene or the leptin receptor, genetic constellations that are relatively rare in 
humans with obesity.  
Resistance arteries from the mesentery (Oltman et al., 2006) and skeletal muscle vascular 
beds (Frisbee et al., 2001) of obese Zucker rats exhibit impaired endothelium-dependent 
vasodilation, similar to microvascular dysfunction in obese patients. It has been found that in 
mesenteric arterioles endothelium-dependent relaxation to ACh is preserved at 20 weeks of age, 
but is reduced in older (32-week) obese Zucker rats, suggesting age-dependent progression of 
vasomotor dysfunction (Subramanian et al., 2003). In obese JCR:LA-cp rats, impaired 
endothelium-dependent dilations of mesenteric arteries to ACh has been reported (O'Brien et al., 
1998). Reduced mesenteric (Naderali et al., 2001a) and skeletal muscle (Erdei et al., 2006) 
arteriolar dilation to ACh was also found in rats fed a high fat diet. These studies demonstrated 
microvascular dysfunction in experimental models of obesity and concluded that the reduced 
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 dilation of resistance arteries is primarily due to impaired function of microvascular 
endothelium.  
The vascular endothelium produces and secretes numerous compounds that regulate a variety 
of physiological functions, including vasomotor tone, coagulation, inflammation, permeability 
and cell adhesion (Vane et al., 1990). Among others, nitric oxide (NO) is considered to be one of 
the key molecules in maintaining normal vascular homeostasis and is a major contributor to 
maintaining adequate dilator function of arteries (Loscalzo et al., 1995). Experimental evidence 
indicates that obesity is associated with reduced bioavailability of vascular NO (Erdos et al., 
2002; Frisbee et al., 2001; Naderali et al., 2001b). Oxidative stress occurring in response to 
hyperglycemia (Bagi et al., 2003; Bagi et al., 2004b; Bohlen et al., 1993; Ruderman et al., 1992) 
and hypertension (Jaap et al., 1994; Ungvari et al., 2003) is considered to be one of the key 
factors leading to the reduced NO availability. Evidence also supports that insulin resistance 
(Erdos et al., 2002) and obesity (Erdei et al., 2006; Erdos et al., 2004) are associated with an 
increased vascular production of reactive oxygen species (ROS). In this context, increased 
production of vascular superoxide anion has been shown to lead to inactivation of endothelial 
NO, resulting in a reduced agonist-induced dilation of mesenteric and skeletal muscle 
microvessels of obese mice and rats (Bagi et al., 2003; Bohlen et al., 1993; Frisbee et al., 2001). 
Oltman et al have found that a free radical scavenger, tiron, restored the diminished dilations of 
coronary arterioles in obese Zucker rats (Oltman et al., 2006). Rats fed a high fat diet also 
exhibited enhanced vascular production of superoxide anion, which was associated with reduced 
ACh- and histamine-induced, NO-mediated arteriolar dilations of skeletal muscle arterioles; 
responses were restored by the ROS scavenger, tiron (Erdei et al., 2006).  
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 Excess production of vascular superoxide anion is derived from different ROS-producing 
systems in the vasculature, including NAD(P)H oxidase, xanthine oxidase, uncoupled NO 
synthase and mithochondrial complexes (Wolin, 2000). The primary source of microvascular 
ROS has not yet been identified in obesity. The xanthine oxidase inhibitor, allopurinol partially 
restored ACh- and histamine-induced dilations in skeletal muscle arterioles of obese but not in 
lean rats, whereas the NAD(P)H oxidase inhibitor, apocynin had no significant effects on these 
responses (Erdei et al., 2006). Allopurinol, but not apocynin, also reduced lucigenin enhanced 
chemiluminescense-detected superoxide anion production in carotid arteries of obese rats (Erdei 
et al., 2006). Other studies also found an enhanced vascular xanthine oxidase activity in rabbit 
model of hypercholesterolemia (Ohara et al., 1993) and demonstrated a crucial role for the 
circulating form of xanthine oxidase, which contributes to enhanced production of vascular ROS 
in these animals (White et al., 1996). In humans with hypercholesterolemia, the xanthine oxidase 
inhibitor oxypurinol improved ACh-induced dilations of the brachial artery (Cardillo et al., 
1997).  
Other studies indicated that vascular NAD(P)H oxidase is the major source of superoxide 
anion production in arteries of obese animals. Both obese, ob/ob mice and obese Zucker rats 
exhibited increased NAD(P)H oxidase-derived ROS production as assessed by in vivo electron 
spin resonance (Sonta et al., 2004). Obese Zucker rats demonstrate a reduced insulin-induced 
vasodilation in small coronary arteries, as a result of increased production of ROS by vascular 
NAD(P)H oxidase (Katakam et al., 2005). Increased superoxide anion generation by NAD(P)H 
oxidase was associated with enhanced expression of NAD(P)H subunits p22 and p40-phox in 
coronary vessels of the obese Zucker rat, in which apocynin restored endothelium-dependent 
dilation (Picchi et al., 2006).  
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 Based on the previous studies, it seems that obesity could lead to activation of vascular 
xanthine oxidase and NAD(P)H-oxidase, although their relative contribution to enhanced ROS 
production has yet to be clarified. It is possible that the source of ROS varies in different 
vascular beds and in various animal models of obesity. More intriguingly, NAD(P)H oxidase-
derived superoxide anion could lead to redox-dependent, irreversible activation of xanthine 
oxidase (Berry et al., 2004). ROS, derived either from NAD(P)H or xanthine oxidase may reduce 
the level of NO synthase cofactor, BH4, which in turn leads to NO synthase uncoupling and 
consequent generation of superoxide anion by NO synthase (Alp et al., 2004). This suggests 
existence of multiple enzymes causing enhanced microvascular production of ROS in obesity. 
Potential interactions between ROS producing enzymes (also schematically depicted on Figure 
1) may exaggerate vascular oxidative stress as obesity progresses. Clearly, further studies are 
needed to identify the early events that may initiate microvascular ROS production, which in 
turn leads to inactivation of endothelium-derived NO in resistance arteries in obesity. 
In addition to NO, other important mechanisms contribute to dilations of resistance arteries, 
such as those mediated by endothelium-derived hyperpolarizing factor (EDHF). In comparison to 
NO, EDHF-mediated arteriolar dilation is believed to be less sensitive to oxidative stress. In this 
context, dilations mediated by EDHF can persist and may even compensate for the loss of NO-
mediated vasodilation in obesity. In support of this scenario, a study has found that ApoE and 
LDL receptor-deficient mice fed a high-cholesterol diet exhibit a preserved EDHF-mediated 
dilation to ACh in cremaster muscle arterioles (Wolfle et al., 2005). Ellis et al. described an 
augmented, EDHF-mediated dilation of small mesenteric arteries both in wild type and LDL 
receptor knockout mice fed a high fat diet (Ellis et al., 2008). A maintained ACh-induced, EDHF 
mediated dilations have been reported in coronary arterioles of high fat diet fed, obese rats 
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 (Feher et al., 2010).  It is known that activation of Ca2+-activated small (SKCa) and intermediate 
(IKCa) conductance K+ channels play a crucial role in EDHF-mediated vasodilation (Burnham et 
al., 2002; Bychkov et al., 2002; Dora et al., 2008). The large conductance Ca2+-activated K+ 
channels (BKCa) have been also implicated in EDHF response in porcine coronary vessels 
(Edwards et al., 2000), although their contribution to EDHF-mediated dilation seems dependent 
on the applied pharmacological stimulus (Edwards et al., 2000), and does not occur in some 
types of arteries, such as mesenteric (Dong et al., 2000) or hepatic vessels (Edwards et al., 1999). 
In the study by Ellis et al. the augmented, EDHF-mediated dilations to ACh were effectively 
blocked by KCa channel inhibitors, apamin and charybdotoxin in mesenteric arteries of obese 
mice (Ellis et al., 2008). Interestingly, in coronary arterioles of obese, but not in lean rats, the 
BKCa channel inhibitor, iberiotoxin exerted a marked inhibitory effect on EDHF-mediated 
dilations (Feher et al., 2010). No change in KCa channel function has found in small mesenteric 
arteries of obese Zucker rats, while the magnitude of EDHF-mediated dilation was reduced, due 
to impaired connexin-dependent cell-to-cell signaling (Young et al., 2008). Thus, the function of 
SKCa and IKCa channels seems preserved and the EDHF response can be maintained early on in 
obesity.  
The function of BKCa channels, however, can be affected as obesity progresses and 
atherogenic dyslipidaemia and diabetes develop. Studies by Burnham et al. (Burnham et al., 
2006) and by Lu et al. (Lu et al., 2008) found impaired BKCa channel-mediated dilations in 
mesenteric arteries of Zucker Diabetic Fatty rats; animals with insulin resistance and manifest 
hyperglycemia. Moreover, high fructose containing and atherogenic diet in swine was associated 
with reduced BKCa channel-mediated dilation of coronary arteries (Borbouse et al., 2009; 
Dimitropoulou et al., 2002). These observations suggest a pathological role for high glucose and 
   10 
 
 
 atherogenic dyslipidaemia in the development of impaired BKCa channel function and 
consequently diminished arterial dilation. It is known that BKCa channels are primarily expressed 
in vascular smooth muscle cells, where they are activated by high concentrations of local [Ca2+]i 
(10-100 μM), also called Ca2+ sparks, reviewed in (Jaggar et al., 2000). It is possible that the 
impaired BKCa channel function is associated primarily with enhanced, smooth muscle-
dependent arteriolar tone in obesity and diabetes. In this context, a study by Mokelke at al. has 
found a decreased Ca2+ spark activity and reduced outward K+ current in coronary microvascular 
smooth muscle cells of the diabetic dyslipidaemic swine, alterations that were associated with an 
impaired baseline coronary blood flow (Mokelke et al., 2005). 
It still remains unknown how the function of certain KCa channel could persist early on in 
obesity, while others become impaired, especially as the disease progresses. In obesity 
microvessels are exposed to increasing levels of harmful stimuli, such as ROS. Experimental 
evidence shows that inhibiting individual KCa channels is insufficient to block the EDHF 
response in small arteries (Dong et al., 2000; Griffith, 2004). Thus, one can speculate that in 
disease, KCa channels that are less sensitive for harmful stimuli may replace the function of other, 
likely more susceptible KCa channels to maintain the overall EDHF response and vasodilation. 
Inhibition of KCa channels may occur via the oxidation of critical SH groups (Cai et al., 1997). It 
is plausible that SKCa, IKCa and BKCa channels differ in their susceptibility to ROS-dependent 
inhibition, providing a potential mechanistic explanation for this phenomenon. Further studies 
are needed to explore how oxidative stress affects KCa channel characteristics in microvessels 
and whether this changes as obesity progresses.  
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 Summary of this section 
To conclude this section it is established that obesity is associated with a reduced dilator 
function of both conduit and resistance arteries. There is a paucity of experimental data in man 
regarding the exact underlying mechanisms behind the vasomotor dysfunction. On the basis of 
animal studies it possible that vascular oxidative stress is the main contributor for the 
development of microvascular dysfunction in obesity, which is characterized by reduced 
endothelium-dependent, NO-mediated arteriolar dilation (Figure 1). The exact source of ROS 
production has yet to be elucidated in obesity. Evidence also suggests that EDHF-type dilations 
of resistance arteries persist over the course of obesity, due to the maintained function of SKCa 
and IKCa channels. The function of BKCa channels, however, becomes compromised especially 
when obesity progresses and other co-morbid diseases develop, such as type 2 diabetes, 
dyslipidaemia and hypertension. Understanding the sequence of pathological events and that 
could initiate ROS production will provide a rationale for therapeutic interventions to restore NO 
bioavailability and to prevent dysfunction of KCa channels in resistance arteries in obese patients. 
 
   12 
 
 
 Role for adipose tissue-derived factors in eliciting increased vascular ROS production 
In order to interfere with pathological production of vascular ROS in obesity, it is 
important to identify mechanisms that are responsible for initiating the sequence of deleterious 
events. An important role for atherogenic dyslipidaemia, oxidized low-density lipoproteins, free 
fatty acids in the development of obesity- and insulin resistance-related ROS production is 
discussed in more detail in a recent comprehensive review (Bashan et al., 2009). Recently, it has 
been posited that in obesity the altered function of ROS-producing enzymes could arise from the 
adverse effects of adipocyte- and perivascular adipose tissue (PVAT)-derived factors 
(adipokines) (Berg et al., 2005; Kadowaki et al., 2005). In obesity, the normal endocrine 
function of adipocytes is altered and may be manifested as reduced adiponectin (Kadowaki et al., 
2005) and elevated circulating and tissue levels of leptin, resistin, interleukin 6 and TNFα (Berg 
et al., 2005). Several recent investigations focused on elucidating adverse vascular effects of 
secreted adipokines in obesity. In this context, Knudson et al have found that higher, 
pathological concentration of leptin (625 pmol/l) attenuated dilation to ACh of coronary arteries 
in normal dogs, whereas physiological concentrations (250 pmol/l) were without effect (Knudson 
et al., 2005). It has been shown that leptin promotes oxidative stress in cultured endothelial cells 
(Korda et al., 2008). In porcine coronary arteries, exposure to resistin elicited a reduced dilation 
to bradykinin, via induction of ROS production (Kougias et al., 2005). Dick et al. have found a 
reduced bradykinin-induced dilation of canine coronary arteries exposed to resistin; an effect 
which was however independent from increased ROS production and was not affecting 
endothelial production of NO or PGI2 (Dick et al., 2006). Moreover, TNFα via increasing 
NAD(P)H oxidase-derived ROS production has been implicated in the development of coronary 
arterial dysfunction in obese Zucker rats (Picchi et al., 2006).  
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 It still remains unclear how adipokines elicit increased vascular ROS production. In their 
study of human saphenous vein endothelial cells, Verma et al. demonstrated that resistin 
increases expression of endothelin-1 (Verma et al., 2003). Endothelin-1 is a potent 
vasoconstrictor, but it is also an important mediator of enhanced ROS production in the 
vasculature. Over-expression of resistin leads to increased NAD(P)H oxidase activity via 
increasing the levels of NOX2, NOX4, and p47phox in the rat heart, and results in marked 
nitrotyrosine formation (Chemaly et al., 2011). Decreased eNOS levels were also observed in 
human coronary artery endothelial cells incubated with resistin (Chen et al., 2010). The authors 
also demonstrated resistin’s ability to impair mitochondrial respiratory chain function and 
indicate the mitochondria as a key source of ROS production induced by resistin exposure (Chen 
et al., 2010).  IL-6 has been shown to up-regulate AT1 receptor gene expression, which resulted 
in an increased angiotensin II-mediated ROS production in vascular smooth muscle cells 
(Wassmann et al., 2004). Recently, Hung et al. have shown that IL-6 increased the stability of 
caveolin-1, a negative regulator of eNOS. As a result of the increased inhibition of eNOS, NO 
bioavailability was reduced in the presence of IL-6 (Hung et al., 2010). In the study by Payne et 
al, leptin, likely to be released from PVAT, elicited reduction of bradykinin-induced coronary 
relaxation in a swine model of metabolic syndrome; a response, which was mediated by 
activation of PKC (Payne et al., 2010).  The importance of PVAT in regulating vascular 
resistance and its potential role in development of microvascular dysfunction in obesity are 
discussed in more details in other papers in this themed issue and the reader is directed to a more 
detailed comprehensive recent review (Li et al., 2010).  
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 Summary of this section 
Several recent studies indicate that adipokines, such as leptin, resistin, IL-6 and TNFα 
exert adverse effects on vasodilator function in animals with experimental obesity. These effects 
in part are mediated by elevated ROS production in the vascular wall. Exact mechanisms by 
which adipokines increase vascular ROS production are not entirely understood, but can be 
mediated by adipokine-dependent induction of endothelin-1 and angiotensin II production or 
could be attributed to direct activation of specific signaling pathways, such as PKC, known to be 
involved in ROS generation.   
Less is known about the pathological role of adipokines in humans. Although higher 
leptin concentrations were associated with impaired arterial distensibility in healthy adolescents 
(Singhal et al., 2002), acute subcutaneous administration of leptin unexpectedly increased flow-
mediated dilation of the brachial artery (Brook et al., 2007). Furthermore, in obese women, 
leptin concentrations did not predict the impaired flow-mediated dilation of the brachial artery 
(Oflaz et al., 2003). The apparent discrepancy between animal and human studies is not known 
and clearly requires further investigation.  
 
Coronary microvascular responsiveness in obesity – different from that of the periphery? 
Increase in body mass, muscular or adipose type, requires a higher cardiac output and 
expanded intravascular volume to meet the elevated metabolic requirements (Lavie et al., 1986). 
It is widely accepted that obesity is independently associated with left ventricular hypertrophy 
(Abel et al., 2008). This is considered to be an early adaptation of cardiac function, which 
accommodates for the higher hemodynamic and metabolic demand in obesity. It has been posited 
that in “uncomplicated” obesity - lack of serious co-morbid conditions such as hypertension and 
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 diabetes - the increased left ventricular mass can be appropriate for body size (Iacobellis, 2004). 
Cardiac adaptation in obesity also implies changes in coronary circulation, which aims to provide 
adequate blood flow to meet the increased metabolic demand. Adaptation in coronary vessels 
seems particularly important, since in the coronary circulation oxygen extraction is near maximal 
and any mismatch between blood supply and metabolic demand would deteriorate myocardial 
contractile function (Tune et al., 2004).  
Could adaptation of the coronary circulation meet the increased metabolic demand in obesity? 
To answer this question several studies set out to investigate whether myocardial blood flow 
differs in obese subjects. Myocardial blood flow can be measured non-invasively in units of 
milliliters of blood per minute per gram of myocardium at baseline and after pharmacological 
challenge. Most investigations of the coronary circulation in humans have employed positron 
emission tomography (PET) for flow measurements. Myocardial blood flow, as measured by 
PET, has been found to be significantly reduced in post-menopausal women with obesity (Martin 
et al., 2005). In this study the impaired myocardial blood flow was negatively correlated with 
waist/hip ratio (Martin et al., 2005). In contrast, pre-menopausal women with similar levels of 
obesity exhibited a higher myocardial blood flow at baseline when compared to lean subjects, 
while no difference was detected between lean and obese men (Peterson et al., 2008). Increased 
myocardial blood flow has also been described in postmenopausal obese women without 
coronary artery disease, however the increase in resting blood flow was associated with a 
significantly reduced coronary flow reserve, as defined by the ratio of coronary flow under 
maximal dipyridamole-induced vasodilatation to coronary flow under resting conditions 
(Motivala et al., 2008). A study by Schindler et al. compared myocardial blood flow between 
lean, overweight and obese subjects involving both men and women using PET imaging 
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 (Schindler et al., 2006). They found that at baseline, myocardial blood flow did not differ among 
the three groups, but cold pressor test- or dipyridamole-induced increases in blood flow were 
significantly reduced in obese patients, when compared to lean individuals (Schindler et al., 
2006). While gender did not correlate with dilator capacity of coronary vessels there was a 
significant negative impact of age in this study. By using cardiac magnetic resonance imaging 
neither the resting myocardial blood flow nor the adenosine-induced hyperemic flow were 
correlated with obesity in asymptomatic patients in the Multi-Ethnic Study of Atherosclerosis 
(MESA), which involved 222 men and women (Wang et al., 2006). The majority of these 
clinical studies demonstrated that basal myocardial blood flow is not compromised in obese 
subjects. However, alterations may manifest when the coronary circulation is pharmacologically 
challenged to mimic the increased metabolic demand in obesity. Thus, it seems, it is the response 
of myocardial blood flow to pharmacological or physiological stimuli, which could uncover the 
presence of pathological alterations in the coronary circulation in obesity. The important 
question however remains whether the basal or stimulated increase in myocardial blood flow is 
able to meet the elevated metabolic demand in obesity. A series of experiments performed in 
dogs with experimental obesity and metabolic syndrome show that in spite of unaltered basal and 
stimulated coronary blood flow rate there could be a mismatch between myocardial perfusion 
and metabolism, as estimated by the rate of oxygen consumption (Borbouse et al., 2010; Setty et 
al., 2003). These experiments suggest that even an elevated coronary blood flow is unable to 
meet metabolic requirements in obese animals. This phenomenon has yet to be confirmed in 
obese patients. Furthermore, in order to understand the nature of altered tissue perfusion it seems 
important to elucidate the cellular mechanisms, which regulate coronary arteriolar diameter and 
adjust blood flow to enhanced metabolic demand in obesity. 
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 The coronary circulation matches blood flow with metabolic requirements by coordinating the 
vascular resistance in different-sized coronary vessels, which is governed by distinct 
mechanisms, such as the myogenic flow or metabolic control of arterial diameter (Chilian, 1997; 
Jones et al., 1995). The large, conduit coronary arteries exert small if any resistance; resistance 
to blood flow rises as the vessel diameter decreases in arterioles with a diameter of less than 300 
μm, in man. These aforementioned underscore the need for direct examination of the function of 
coronary resistance arteries to understand how their vasomotor behavior changes and how it 
relates to coronary blood flow alterations in obese patients. 
At present, convincing evidence of the impact of human obesity on vasomotor regulation of 
coronary arterioles and the exact underlying mechanisms are lacking. Direct investigation of 
coronary arteriolar vasomotor function and diameter changes can be performed by 
videomicroscopy of isolated microvessels obtained from the heart of obese patients (Fulop et al., 
2007; Szerafin et al., 2006) or from the heart of animals with genetically-induced (Bagi et al., 
2004a) or diet-induced, experimental obesity (Feher et al., 2010; Jebelovszki et al., 2008). In this 
preparation, isolated arterioles develop a spontaneous myogenic tone in response to increases in 
intraluminar pressure. The magnitude of the myogenic tone depends on the level of intra-
arteriolar pressure, which can be sensed by vascular smooth muscle cells and can be modulated 
by factors released from vascular endothelium. It is believed that the spontaneously developed 
tone in isolated coronary arterioles is comparable in magnitude to those in vivo. Studies from our 
laboratory demonstrated that in coronary arterioles the magnitude of myogenic tone does not 
differ between lean and obese patients (Fulop et al., 2007). Furthermore, in an animal model of 
diet-induced obesity, increases in intraluminal pressure elicited similar diameter changes in 
coronary arterioles from lean and obese rats (Erdei et al., 2006).  
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 The intrinsic myogenic tone also establishes a diameter reserve allowing microvessels to 
dilate in response to metabolic, neuronal and other vasomotor stimuli. Vasodilator function can 
be studied in isolated coronary arterioles in vitro, where diameter changes in response to agonist 
stimulation is continuously recorded. Coronary arterioles from the heart of obese patients exhibit 
a reduced endothelium-dependent, bradykinin-induced dilation (Fulop et al., 2007). Oltman et al. 
have investigated the progression of coronary arterial dysfunction in obese Zucker rats and found 
that coronary arteriolar dilation to ACh was preserved in 16-24 week old animals, but dilations 
became reduced in 28-36 week old rats (Oltman et al., 2006). Katakam et al. reported that in 12-
week old obese Zucker rats ACh-induced dilation of small coronary arteries was preserved, 
although a reduced vasodilation to insulin was also reported in this study (Katakam et al., 2005). 
Coronary arterioles from pigs fed a high fat diet to induce obesity exhibited only modest 
impairment of dilation to bradykinin (Henderson et al., 2004), whereas coronary dilation to ACh 
was found to be preserved in high fat fed, obese rats (Jebelovszki et al., 2008). More intriguing, 
Prakash et al. have reported that ACh-induced dilation of coronary arterioles in obese Zucker rats 
is markedly enhanced (more than 25% increase in diameter, when compared to lean animals) 
(Prakash et al., 2006).  
Although observations from studies on large conduit arteries suggest detrimental effects of 
obesity on vascular responsiveness (Hashimoto et al., 1998; Kapiotis et al., 2006), vasomotor 
tone and agonist-stimulated dilator function of coronary microvessels may remain intact, 
especially at the early state of the disease. This phenomenon implies that in obesity, 
vasoregulatory mechanisms intrinsic to the microvascular wall may be protected from those 
pathological factors that are detrimental to other types of vessels in the periphery. It is known 
that the dilator function of small coronary arteries is mediated by the release of autacoids from 
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 the endothelium including nitric oxide (NO) and endothelium-derived hyperpolarizing factor 
(EDHF). Experimental evidence suggests that endothelial availability of NO is reduced in 
coronary arterioles in obesity, this however is compensated for by various other vascular 
mechanisms. For example, emerging evidence indicates that the same ROS derivates, which 
otherwise would impair microvascular function in peripheral vessels, may act as prominent 
vasodilators in the coronary microcirculation. In this context, Matoba et al. demonstrated that a 
major dilator factor released from the endothelium of porcine coronary microvessels is H2O2 
(Matoba et al., 2003). Coronary arterial microvessels from the human heart also generate H2O2 
from endothelial cells as a major contributor of coronary arteriolar dilation (Miura et al., 2003). 
The underlying mechanism of H2O2-mediated dilation varies, but studies show that H2O2 exerts 
its vasodilator effects via activating KCa channels (Hayabuchi et al., 1998; Matoba et al., 2003; 
Miura et al., 2003). Thus, it has been proposed that H2O2, via eliciting KCa channel activation 
potentially acts as an EDHF in coronary microvessels (Feletou et al., 2006; Shimokawa et al., 
2004). Other studies demonstrate that H2O2-induced vasodilation is mediated through the release 
of NO from the endothelium (Hirai et al., 2000) or is partially mediated by cGMP formation in 
vascular smooth muscle cells (Fujimoto et al., 2001). Regardless of the mechanisms of action, 
H2O2 could maintain dilator function of coronary arterioles in obesity, even if the availability of 
NO is compromised (Figure 1 and 2). Interestingly, a study by Saitoh et al. indicates that H2O2, 
released from cardiac myocytes, couples coronary blood flow to myocardial oxygen 
consumption (Saitoh et al., 2006), providing further importance for H2O2 in the coronary 
circulation. Whether or not cardiac myocyte derived H2O2 contributes to the regulation of 
coronary arteriolar diameter in obesity requires further investigation.  
   20 
 
 
 A reduced availability of endothelial NO could be associated with enhanced sensitivity to NO 
in the vascular smooth muscle cells. In this context, studies from our laboratory provided 
evidence for enhanced NO sensitivity of coronary arterioles isolated from obese rats fed a high 
fat diet (Jebelovszki et al., 2008). The enhanced sensitivity of coronary arterioles to NO is 
mediated by increased activity of soluble guanylate cyclase (sGC) in the coronary arteriolar wall 
(Jebelovszki et al., 2008). Enhanced dilations of coronary arterioles to the NO donor, sodium 
nitroprusside, have also been described in female pigs fed a high fat diet (Woodman et al., 2004) 
and in mesenteric arterioles of obese Zucker rats (Oltman et al., 2006). Similar results were 
obtained in humans, showing that NO donor-induced coronary arteriolar and brachial artery 
dilations were enhanced in patients with obesity (Fulop et al., 2007). Thus, it seems the enhanced 
sensitivity of smooth muscle cells to NO may also lead to compensation of the impaired NO-
mediated coronary signaling in obesity. Chronic oxidative and nitrosative stress can lead to 
inactivation of sGC over time (Munzel et al., 2005) and also could diminish KCa channel 
function (Figure 1). The question that remains to be answered is to what extent and how long the 
up-regulation of sGC, and H2O2-dependent activation of vascular KCa channels may be able to 
compensate for the reduced NO-mediated signaling as obesity progresses?  
 
Summary of this section  
Clinical studies have found that basal myocardial blood flow is not compromised in obese 
subjects, which however becomes inadequate when cardiac metabolism is stimulated. Unlike 
peripheral vessels, coronary microvessels actively adapt to match higher metabolic demand by 
maintaining their vasodilator function. Evidence indicates that this adaptation involves various 
cellular pathways, such as the compensatory increased production of H2O2, which serves an 
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 important vasodilator factor in the coronary circulation. It is of particular importance that in spite 
of this compensatory mechanism and maintained vasodilator function, coronary blood flow is 
unable to meet higher metabolic requirements in obesity. Understanding compensatory 
mechanisms in coronary arteriolar wall seems important, as they could provide insight into the 
sequence of pathological events in obesity and could be harnessed for therapeutic purposes.  
 
Altered microvascular responsiveness in adipose tissue  
Adipose tissue can represent 18% and 24% of body weight in normal men and women, 
respectively; as much as 52% and 74% of body weight in obese man and women, respectively 
(Leibel et al., 1995). Adipocytes perform an important endocrine function by secreting numerous 
cytokines, hormones, and bioactive peptides. Upon secretion into the bloodstream, these 
adipokines, such as adiponectin, leptin, resistin, interleukin 6 and TNFα have a key impact on 
skeletal muscle and liver function to regulate energy homeostasis and metabolism (Kadowaki et 
al., 2003). In addition to their systemic action adipokines may exert paracrine effects on 
vasoregulatory mechanisms in adipose tissue microvessels (Figure 2). This does not simply 
reflect systemic vasomotor dysfunction, but could contribute to the development and also 
maintenance of adiposity. Expansion in addition to reduction of the fat mass relies on the 
function of the adipose tissue microcirculation. An important interaction between microvessels 
and adipocytes has been recently envisioned (Rutkowski et al., 2009). It is known that adipose 
tissue possesses a dense network of microvessels ensuring adequate tissue perfusion, exchange 
of nutrients and oxygen. The adipose tissue vasculature delivers lipids to their storage depot in 
the adipocytes and also exports nutrients in response to metabolic need. It is plausible that 
alterations in the responsiveness of adipose tissue microvessels have a significant impact on 
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 adipose tissue metabolism and nutrient trafficking. For example, insufficient adipose tissue 
perfusion may result in local hypoxia, which increases the levels of hypoxia inducible factor, 
HIF-1α in adipocytes (Halberg et al., 2009; Trayhurn et al., 2008). HIF-1α may lead to up-
regulation of various inflammatory adipokines, such as interleukin-6, TNFα and monocyte 
chemotactic protein-1 (Halberg et al., 2009). Upon secretion into bloodstream these adipokines 
will cause damage in systemic microvessels (Trayhurn et al., 2008) and also elicit dysfunction of 
adipose tissue arterioles, further exaggerating dysregulation of adipose tissue microcirculation.  
Given the importance of adipose tissue microcirculation, it is surprising that little attention 
has been devoted to elucidate alterations in microvascular responsiveness in the adipose tissue. 
Studies in adipose tissue microvessels are particularly lacking in obese patients. Early in vivo 
reports on autoregulation in the canine inguinal fat pad suggest that the microvessels possess a 
pressure sensitive myogenic response, which contributes to the regulation of adipose tissue 
perfusion (Nielsen et al., 1971). In isolated adipose tissue arterioles of the rat myogenic tone 
develops in response to an increase in intraluminal pressure (Undavia et al., 2003). In humans, it 
has been found that subcutaneous adipose tissue arteries develop myogenic tone in response to 
an increase in pressure, which is due to the activation of phospholipase C, diacyl-glycerol and 
protein kinase C pathways (Coats et al., 2001b). In healthy volunteers resistance arteries from 
gluteal subcutaneous fat exhibit dose dependent relaxation to histamine, which is mediated by 
both muscular histamine H2 receptors and endothelial histamine H1 receptors (Van de Voorde et 
al., 1998). Activation of H1 receptors by histamine was associated with endothelial release of 
NO in adipose tissue arterioles (Van de Voorde et al., 1998). In another study, ACh elicited 
EDHF-type, phospholipase A2- and cytochrome P450-inhibited relaxation of subcutaneous 
adipose tissue resistance arteries in healthy individuals (Coats et al., 2001a). In subcutaneous fat 
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 arteries of healthy subjects it has been shown that increasing concentrations of insulin reduced 
noradrenaline-induced vascular tone in a dose dependent manner (McNally et al., 1995). Thus, it 
seems that adipose tissue microvessels use similar pathways to regulate their diameter compared 
to other types of microvessels in the body. Whether these vasoregulatory pathways in adipose 
tissue microvessels are similarly affected by obesity as compared to other types of microvessels 
is not entirely understood. In the study by Greenstein et al. responses of subcutaneous adipose 
tissue arterioles from lean or obese patients with metabolic syndrome were studied. Compared to 
controls, contraction of arterioles to norepinephrine or 60 mM KCl were unaffected by obesity, 
but relaxation induced by ACh was significantly impaired (Greenstein et al., 2009). The authors 
suggested that local inflammation in perivascular adipose tissue, mediated by TNFα or IL-6 and 
oxidative stress, interferes with adiponectin-induced NO release and primarily responsible for 
vasomotor dysfunction of adipose tissue arterioles in obese patients (Greenstein et al., 2009).  
 
Summary of this section 
Several studies demonstrate the feasibility of studying vasomotor function of adipose tissue 
arterioles in healthy and obesity subjects. Whether vasomotor changes in adipose tissue 
arterioles, via endothelium- and smooth muscle-dependent cellular pathways contribute to the 
development of obesity and whether these pathological alterations change as obesity progresses 
is not known, and clearly requires further investigation. Expanded adipose tissue represents 
primary therapeutic target to prevent obesity-related vascular complications. Emerging evidence 
also indicates that specific alteration(s) in adipose tissue microcirculation may contribute to the 
development of insulin resistance and obesity. Demonstrating that changes in microvascular 
responsiveness of adipose tissue arterioles could modulate adipose tissue metabolism, and affect 
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 lipid and nutrient trafficking, may allow for the discovery of novel therapeutic targets for 
intervention.  
 
Therapeutic attempts to improve altered microvascular responsiveness in obesity 
There is no doubt that physical exercise, balanced diet and weight loss are the primary 
mediators in the prevention of cardiovascular diseases in obesity. Unfortunately in Western 
Society this simple advice has not resulted in major breakthroughs in fighting obesity and 
obesity-related cardiovascular morbidity and mortality. Meanwhile, enormous efforts are being 
made by pharmaceutical companies to search for new targets to treat and prevent life-threatening 
cardiovascular complications in obese patients. Effective drugs to treat obesity have proven 
enormously difficult to develop. Many previous (but already withdrawn) and currently available 
anti-obesity drugs target the brain to modify appetite, but the targeted brain circuits of these 
drugs unfortunately overlap with those that control other important functions in the body raising 
the risk of serious side effects. Even if they were safe, patients would have to take a drug for 
several years. There are several drugs, however, that are frequently prescribed and taken by 
patients with cardiovascular diseases, those that may also be beneficial – perhaps only indirectly 
– in targeting microvascular dysfunction in obesity and insulin resistance. These include statins 
(Grundy et al., 2005), angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (McFarlane et al., 2003) and insulin sensitizers, metformin and thiazolidinediones 
(TZDs) (Hill et al., 2009; Jay et al., 2007). Here, we only provide examples of attempts for 
pharmacological interventions with these drugs, in which the main focus was to prevent 
vasomotor abnormalities in obese subjects. Convincing evidence for direct beneficial effects of 
these and other drugs on microvessels in obesity is lacking at present. Such demonstration is 
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 hampered by issues regarding to the direct investigation of microcirculation in humans and the 
obvious impact of these drugs on other pathological factors, such as atherogenic dyslipidaemia, 
insulin resistance and elevated blood pressure.  
Statins. Statins lower plasma lipid levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis, and are known to 
reduce cardiovascular morbidity and mortality (Goldberg et al., 1998). Statins may improve 
microvascular function both via affecting lipid metabolism and via direct effects on the 
vasculature (Wilson et al., 2001). In a study by Nagashima et al., twenty-four obese male 
subjects were randomly assigned to receive pitavastatin (2 mg/day) or placebo for 2 weeks. An 
oral fat loading test was conducted, which elicited a marked increase of serum triglyceride level 
and decreased flow-mediated dilation of brachial artery in the placebo group. In the pitavastatin 
group the increase in postprandial triglyceride was attenuated and the postprandial brachial artery 
relaxation was restored (Nagashima et al., 2010). Thus, statins may improve vascular function 
due to their effect on dyslipidaemia, but data concerning their direct microvascular effects and 
the underlying mechanisms in obesity are limited.  
Statins may facilitate the synthesis of endothelial NO (Feron et al., 2001) and also could 
reduce ROS production in the vascular wall (Mason et al., 2004; Wassmann et al., 2002). In this 
context, treatment of obese Zucker rats with rosuvastatin (25 mg/kg daily) for 12 weeks 
improved ACh-induced relaxation of epineural arterioles by preventing oxidative and nitrosative 
stress (Oltman et al., 2008). Pitavastatin treatment  (3 mg/kg) for 8 weeks in the obese Zucker rat 
also restored the diminished ACh-induced relaxation and normalized angiotensin II-induced 
contraction of the aorta, which was due to the reduction of endothelial, NADPH-oxidase derived 
superoxide production and restoration of eNOS cofactor, tetrahydrobiopterin (BH4) levels. 
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 Interestingly, the effects of pitavastatin was due to the down-regulation of type 1 angiotensin II 
(AT1) receptor and NADPH-oxidase subunit, gp91phox expression and also to the upregulation 
of GTP cyclohydrolase I, the rate limiting enzyme of BH4 synthesis (Shinozaki et al., 2007). In 
the obese Zucker rat 10-week atorvastatin or simvastatin treatments were equally effective at 
improving the ACh-induced, endothelium-dependent vasodilation of skeletal muscle 
microvessels via increasing the vascular availability of NO (Goodwill et al., 2009). The 
beneficial effect of statins was associated with the reduction of inflammatory biomarkers, such as 
interleukin-10 and TNFα in these animals (Goodwill et al., 2009). Rosuvastatin treatment (2 
mg/kg daily) for 4 weeks improved dilator responses to ACh and iloprost in the basilar artery of 
the obese Zucker rat, which was associated with the reduction of NAD(P)H-oxidase derived 
superoxide production (Erdos et al., 2006). Interestingly, beneficial effects of rosuvastatin were 
observed after one-day of treatment (2 mg/kg). This study was the first to suggest that statins, 
independent of their lipid lowering action improve vasomotor function. (Erdos et al., 2006). 
Thus, it plausible that statins are beneficial in preventing microvascular dysfunction in 
obesity. This effect can be attributed to the concomitant reduction of oxidative stress and/or to 
the limitation of vascular pro-inflammatory signaling mechanisms. Whether the effects are direct 
on microvascular wall or only due to the systemic effect of statins on atherogenic dyslipidaemia 
requires further investigations. 
ACE inhibitors in obesity. It has been proposed that ACE inhibitors improve insulin 
resistance in type 2 diabetic patients (Abuissa et al., 2005; Andraws et al., 2007). Both ACE-
inhibitors and angiotensin receptor blockers (ARBs) were associated with reduced incidences of 
new-onset diabetes among patients with essential hypertension (McFarlane et al., 2003). Orally 
administered ACE inhibitor, imidapril (10 mg/kg) improved insulin sensitivity in obese Zucker 
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 rats, which was associated with reduction of systemic blood pressure and increased blood flow in 
the liver and the skeletal muscle (Nawano et al., 1999). In a study by Duarte et al., obese Zucker 
rats were treated with captopril or enalapril (50 mg/kg and 10 mg/kg, respectively) and 
endothelium-dependent relaxation of isolated aortic rings was studied. They found that both 
captopril and enalapril improved insulin resistance of obese Zucker rat. Interestingly, only the 
sulfhydryl group containing captopril augmented the impaired endothelium-dependent aortic 
relaxation in obese animals (Duarte et al., 1999). Treatment of obese Zucker rats with the ACE 
inhibitor enalapril (20 mg/kg), improved ACh-induced relaxation of epineural arterioles by 
preventing oxidative and nitrosative stress (Oltman et al., 2008). Similar results were obtained 
when obese Zucker rats were treated with a dual inhibitor of ACE and neutral endopeptidase 
(NEP), AVE 7688 (30 mg/kg) in epineuronal arterioles (Davidson et al., 2009). The dual ACE 
and NEP inhibitor, mixanpril (25 mg/kg) restored femoral blood flow to insulin in obese Zucker 
rat and was shown to be more effective than captopril treatment (2 mg/kg) alone (Arbin et al., 
2001). The beneficial effect of dual ACE/NEP inhibitor, AVE 7688 (30mg/kg) over the ACE 
inhibitor, ramipril (1 mg/kg) alone in restoring the impaired insulin sensitivity and endothelial 
dysfunction of the aorta was also demonstrated in obese JCR:LA-cp rats (Russell et al., 2004). In 
this study bradykinin-stimulated coronary flow was also measured in isolated rat hearts. 
Bradykinin-induced coronary flow was improved in both AVE 7688 and ramipril-treated obese, 
JCR:LA-cp rats (Russell et al., 2004).  
The exact mechanism by which ACE inhibitors without or in combination with NEP 
inhibitors improve microvascular responsiveness is not clear. Zhang et al have demonstrated that 
coronary arterioles of high fat-fed dogs exhibit an increased vasoconstriction to angiotensin II, 
likely due to the increased vascular expression of AT1 receptors (Zhang et al., 2005). 
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 Interestingly, recent studies have demonstrated that the local renin-angiotensin-system (RAS) 
can be up-regulated in perivascular adipose tissue (Cassis et al., 2008). Adipose tissue RAS, 
could be one of the sources of increased angiotensin II production (Lu et al., 2007), and not only 
contribute to the development hypertension (Engeli et al., 2005), but also could directly impair 
microvascular function in obesity. To determine whether the effects of ACE inhibitors are solely 
mediated by improving insulin resistance in obese individuals, or are the results of reduced RAS 
activity in adipose tissue, or due to the abolished effects of angiotensin II on the microvascular 
wall, requires further mechanistic insight. 
Insulin sensitizers in obesity. An increase in insulin sensitivity appears to be associated with 
an increase in coronary flow reserve. Insulin resistance therefore can be associated with coronary 
microvascular abnormalities (Dagres et al., 2004).  Insulin resistant patients with type 2 diabetes 
have a lower risk of developing microvascular complications if they are treated with insulin or 
sulfonylureas (UKPDS, 1998).  Insulin sensitizers, such as metformin and PPARγ activator 
TZDs, improve coronary microvascular function in obesity. In a study my Mather et al., patients 
with type 2 diabetes but without other manifested cardiovascular co-morbidities were given 
metformin (500 mg, daily twice) or placebo treatment to evaluate the effect of metformin on 
endothelial cell function, as measured by forearm plethysmography. They found that metformin 
treatment improved ACh-stimulated and flow-induced dilation of the brachial artery (Mather et 
al., 2001). Since there was a significant improvement in insulin resistance with metformin, this 
study concluded that beneficial effects were likely mediated through the insulin resistance 
normalizing action of metformin.  
Moreover, the TZD rosiglitazone has been shown to improve endothelium-dependent 
vasorelaxation of the brachial artery in patients with insulin resistance (Pistrosch et al., 2004; 
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 Regensteiner et al., 2005). The PPARγ activator, rosiglitazone (50 μM/kg, daily) prevented the 
development of hypertension and partially protected against impaired endothelial function 
associated with insulin resistance in the obese Zucker rat (Walker et al., 1999). Rosiglitazone (3 
mg/kg, daily for 1 week) reduced the enhanced vascular ROS production in coronary 
microvessels of obese mice with type 2 diabetes (Bagi et al., 2004a). Thus, it seems that PPARγ 
activators may exert pleiotropic effects, which include increasing insulin sensitivity and direct 
antioxidant properties in improving microvascular function in obesity. On the other hand, use of 
rosiglitazone is associated with increased risk for myocardial infarction (Nissen et al., 2007), but 
the harming effect of rosiglitazone was questioned in the interim analysis of the “Rosiglitazone 
evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes” 
(RECORD) trial (Home et al., 2007).  At present, it seems that there is not enough data available 
to evaluate the cardiovascular safety and efficacy of these drugs (Woodcock et al., 2010). These 
studies also underline the need for clinical investigations addressing the possible effects of drugs 
interfering with PPARγ-regulated microvascular mechanisms in obese patients with insulin 
resistance. 
Antioxidants. Oxidative stress has been shown to impair microvascular function in several 
pathological conditions (Cai et al., 2000). As highlighted in this article, ROS play a key role in 
the development of microvascular dysfunction in obesity. In patients with diabetes, 
administration of the antioxidant Vitamin C prevented the decreased methacholine-induced, 
endothelium-dependent brachial artery relaxation (Beckman et al., 2001). In contrast, other 
studies failed to demonstrate beneficial effects of antioxidant therapy in the prevention of 
vascular complications (Marchioli et al., 2001; Maxwell et al., 2001). For example, vitamin E 
supplementation for 8 weeks did not improve the reduced ACh- and bradykinin-induced dilations 
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 of brachial artery in diabetic patients (Gazis et al., 1999). Recent interventional clinical trials 
also yielded largely negative results, and there has even been some suggestion of harmful effects 
(Willcox et al., 2008). For example, the Heart Outcomes Prevention Evaluation (HOPE) trial 
assessed the antioxidant vitamin E in high-risk patients with cardiovascular disease and diabetes 
and found no effect on cardiovascular outcomes (Hegele, 2000). Even worse, the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) trial found an increased risk for coronary 
events in subjects receiving vitamin-E or beta-carotene as antioxidants (Rapola et al., 1996; 
Rapola et al., 1998; Virtamo et al., 1998). More concerning yet, an increased harm from 
supplemental vitamin E, vitamin-A, and beta-carotene is indicated by the meta-analysis of 15 
clinical trials on cardiovascular outcomes (Vivekananthan et al., 2003). Further studies are 
needed to solve the current paradox regarding the adverse effects of antioxidants versus other 
therapeutics, such as statins and TZDs, the pleiotropic effects of which also include antioxidant 
activity and exert mostly beneficial effects on microvascular function.  
 
While it is accepted that prescription of the pharmacological agents discussed is intended to 
treat sequelae of the metabolic syndrome not associated with microcirculatory dysfunction, 
consideration of their use in targeting the microvessels in the setting of obesity is warranted.  The 
studies highlighted herein not only demonstrate clear pathology and impaired microvessel 
function as a result of obesity, but also discuss the unintended benefits of certain drugs in 
improving microvessel function.  While it is certainly difficult to perform patient follow-up 
studies on microvessel function, develop drug doses aimed specifically at the microcirculation, 
and adapt results from animal models (often with very high drug doses) to patient care, 
implementation of effective pharmachologics presently available to treat microvessel 
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 dysfunction as a means of alleviating the deleterious effects of their pathology would be 
welcomed.  However, consideration of the potential side effects, alongside the hopeful benefit of 
these drugs in the context of obesity induced microvascular dysfunction, needs to be evaluated.       
 
Summary 
Experimental and clinical studies emphasize the importance of those investigations that strive 
to elucidate the mechanisms that regulate tissue perfusion in obesity in order to develop novel 
therapeutics that target the microcirculation in obese patients. Recent studies also raise the 
prospect that modulation of adipose tissue angiogenesis could be a potential therapeutic target to 
reduce adiposity (Cao, 2010), although this possibility requires further investigation and 
validation. Several cardiovascular diseases are associated with a state of chronic, low-level 
inflammation (Gonzalez et al., 2003; Libby et al., 2002). Pro-inflammatory adipokines, such as 
interleukin-6 and TNFα could contribute to the development of microvascular dysfunction in 
obesity. Adipose tissue-derived inflammatory cytokines and adipokines may elicit ROS 
production in adipose tissue microvessels and also in other arterioles in the body. The conclusion 
that ROS may impair vasodilator function (i.e. in skeletal muscle and mesenteric arteries) and 
contributes to enhanced coronary dilations (through H2O2-dependent activation of KCa-channels) 
undoubtedly requires further investigation. Studies have yet to be performed to clearly 
distinguish between the vascular bed specific differences of ROS-mediated signaling, which may 
affect microvascular responses in obesity. Current studies also underline the need for clinical 
investigations addressing the possible effects of drugs affecting microvascular responsiveness 
likely via interfering with adipokine and/or vascular ROS production in obese patients (Figure 
3). A growing number of recent reports document a statistically significant benefit of taking 
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 statins and ACE inhibitors in obese patients. On the other hand, it is possible that interfering with 
vascular signaling may provide further burden to those mechanisms, which are maintaining 
vascular function in disease.  
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 TABLES 
TABLE 1: Clinical (a) and animal studies (b) investigating the impact of obesity on 
vasomotor responses. 
a) Obese Humans   
Reference Vascular bed Response Result 
Kapiotis et al., 2006 brachial artery FMD ↓ 
Hashimoto et al., 1998  brachial artery FMD ↓ 
Kreutzenberg et al., 2003 brachial artery 
forearm res. artery 
FMD 
BK 
↓ 
↓ 
Karpoff et al., 2009 brachial artery FMD ↓ 
Romero-Corral et al, 2010 brachial artery FMD ↓ 
Sivitz et al., 2007  forearm res. artery ACh ↓ 
Martin et al., 2005 myocardium (PET) MBF (rest) 
MBF (CPT) 
↓ 
↓ 
Peterson et al., 2008 myocardium (PET) MBF (rest) ↑ 
Motivala et al., 2008 myocardium (PET) MBF (rest) 
MBF (MFR) 
↑ 
↓ 
Schindler et al., 2006 myocardium (PET) MBF (rest) 
MBF 
(MFR/CPT) 
↔ 
↓ 
Wang et al., 2006 myocardium (MRI) MBF (rest) 
MBF (ADO) 
↔ 
↔ 
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 Fulop et al., 2007 isolated coronary arteriole BK ↓ 
b) Experimental Obesity    
Reference Model, vascular bed Response Result 
Subramanian et al., 2003 OZR, mesenteric (∼20-wk) 
 OZR, mesenteric (∼30-wk) 
ACh  
ACh 
↔ 
↓ 
Oltman et al., 2006 OZR, mesenteric (∼20-wk) 
 OZR, mesenteric (∼30-wk) 
ACh  
ACh 
↓ 
↓ 
Young et al., 2008 OZR, mesenteric (∼12-wk) ACh ↓ 
Ellis et al., 2008 HFD, mesenteric (mouse) ACh ↔ 
Naderali et al., 2001 HFD, mesenteric (rat) ACh ↓ 
O’Brien et al., 1998 JCR:LA-cp rat, mesenteric ACh ↓ 
Frisbee et al., 2001 OZR, cremaster muscle ACh ↓ 
Erdei et al., 2006 HFD, skeletal muscle (rat) ACh ↓ 
Erdos et al., 2004 OZR, cerebral (∼12-wk) ACh ↓ 
Oltman et al., 2006 OZR, coronary (∼20-wk)  
OZR, coronary (∼30-wk) 
ACh 
ACh 
↔ 
↓ 
Katakam et al 2005 OZR, coronary (∼12-wk) ACh ↔ 
Prakash et al.,  2006 OZR, coronary (∼12-wk) ACh ↑ 
Jebelovszki et al., 2008 HFD, coronary (rat) ACh ↔ 
Woodman et al., 2004 HFD, coronary (pig) BK ↓ 
Henderson et al., 2004 HFD, coronary (pig) BK ↔ 
Setty et al., 2003 HFFD, coronary blood flow CBF (rest) ↔* 
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 Borbouse et al., 2010 CBF (exercise) ↔* 
FMD: flow mediated dilation, ACh: acetylcholine, BK: bradykinin: ADO: adenosine, MBF: 
myocardial blood flow, CPT, cold pressor test, MFR: myocardial flow reserve, CBF: coronary 
blood flow, OZR: obese Zucker rat, HFD: high fat diet, HFFD: high fat, high fructose diet. 
*Although no change in CBF was detected the authors found an impaired relationship between 
CBF and myocardial oxygen consumption, MVO(2).  
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 TABLE 2: Clinical and animal studies investigating pharmacologic interventions on the 
vasomotor responses of arteries. 
Reference Model / Vascular Bed Therapy Results 
Nagashima, 2010 Obese man; brachial 
artery 
Pitavastatin [2 mg] Restored FMD after 
oral fat loading test 
Mather, 2001 T2DM man; brachial 
artery 
Metformin [500 mg, twice 
daily] 
↑ ACh dilation and 
FMD 
Pistrosch, 2004 T2DM man/woman; 
brachial artery 
Rosiglitazone [4 mg twice 
daily] 
↑ ACh dilation 
Regensteiner, 2005 T2DM man/woman; 
brachial artery 
Rosiglitazone [4 mg] ↑ FMD 
Beckman, 2001 Healthy man/woman; 
forearm 
Vitamin C [24 mg/min] ↑ methacholine 
dilation 
Gazis, 1999 T2DM man/woman; 
Brachial artery 
Vitamin E [1600 i.u.] ↔ ACh and BK 
dilation 
Wilson, 2001 Porcine: High cholesterol 
diet; coronary arteries 
Simvastatin [80 mg] ↑ BK and Substance 
P dilation 
Oltman, 2008 OZR; epineural arterioles Rosuvastatin [25 mg/kg] ↑ ACh dilation 
Shinozaki, 2007 OZR; aorta Pitavastatin [3 mg/kg] ↑ ACh dilation, ↓ 
Ang II constriction 
Goodwill, 2009 OZR; skeletal muscle 
arterioles 
Atorvastatin 
Simvastatin 
↑ ACh dilation 
Erdos, 2006 OZR; basilar artery Rosuvastatin [2 mg/kg] ↑ ACh and iloprost 
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 dilation 
Nawano, 1999 OZR; liver and skeletal 
muscle 
Imidapril [10 mg/kg] ↑ blood flow  
Duarte, 1999 OZR; aorta Captopril [50 mg/kg] 
 
↑ ACh and SNP 
dilation 
Duarte, 1999 OZR; aorta Enalapril [10 mg/kg] ↔ ACh and SNP 
dilation 
Oltman, 2008 OZR; epineural arterioles Enalapril [20 mg/kg] ↑ ACh dilation 
Davidson, 2009 OZR; epineural arterioles AVE 7688 [30 mg/kg] ↑ ACh dilation 
Arbin, 2001 OZR; femoral artery Mixanpril [25 mg/kg] ↑ insulin induced 
blood flow 
Russell, 2004 Obese JCR:LA-cp rat; 
aorta, coronary artery 
AVE 7688 [30 mg/kg] ↑ coronary BK 
dilation  
Russell, 2004 Obese JCR:LA-cp rat; 
aorta, coronary artery 
Ramipril [1 mg/kg] ↑ coronary BK 
dilation  
Walker, 1999 OZR; mesenteric artery Rosiglitazone [50 µM/kg] ↑ ACh and insulin 
dilation 
Bagi, 2004a db/db mice; coronary 
arteriole 
Rosiglitazone [3 mg/kg] ↑ ACh, NONOate, 
T2DM: type 2 diabetes mellitus, FMD: flow-mediated dilation, OZR: obese Zucker rat, ACh: 
acetylcholine, BK: bradykinin: SNP: sodium nitroprusside. 
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 FIGURE LEGENDS 
 
Figure 1. Endothelial and smooth muscle-dependent signaling mechanisms of resistance 
arteries in obesity. In obesity, pathological alterations of adipocytes develop, which could lead 
to dysfunction of microvascular endothelium. Adipokines, such as leptin, resistin, TNFα and IL-
6 has been directly or indirectly – via increasing endothelin-1 (ET-1) and angiotensin II (Ang II) 
production – implicated in inducing enhanced reactive oxygen production. Enhanced production 
of vascular superoxide anion (O2-.) is due to the activation of various oxidases in the endothelial 
cells, such as NADP(H)-oxidase (NOX) and xanthine-oxidase (XOX). O2-. interacts with nitric 
oxide (NO) to form peroxynitrate (ONOO-) and to reduce NO availability. O2-.  also reduces the 
level of NO synthase cofactor, tetrahydrobiopterine (BH4) and an uncoupled NO synthase further 
generates O2-.. On the other hand, O2-. can be converted to hydrogen peroxide (H2O2) by 
superoxide dismutase, and it may activate various calcium-activated potassium channels, such as 
SK, IK and BK channels or the soluble guanylate cyclase (sGC) to maintain dilator function of 
arterioles, particularly in coronary microvessels.  
 
Figure 2. Effects of adipokines on vasomotor function of arterioles. This schemiatic draw 
illustrates that the degree of vasodilation may vary in various vascular beds in obesity; as shown 
here in skeletal muscle and coronary resistance arteries, although they are exposed to the same 
level of circulating adipokines (leptin, resistin, TNFα and IL-6). Reactive oxygen species (ROS) 
interact with endothelium-derived NO, which results in a diminished vasodilator response in 
skeletal muscle arterioles. The inability of insulin to produce NO and thereby elicit vasodilation 
of skeletal muscle microvessels may also limit the insulin-mediated muscle glucose uptake. On 
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the other hand, the ROS derivate, H2O2 serves as a potent vasodilator in the coronary arterioles, 
which aims to maintain vasodilator responsiveness in the coronary microcirculation. 
 
Figure 3. Adipose tissue microcirculation in obesity. In obesity, during expansion of adipose 
tissue phenotypic changes of adipocytes occurs, which results in increased production of leptin, 
resistin, tumor necrosis factor α (TNFα) and interleukin-6 (IL-6). In addition to their systemic 
actions, these adipokines may locally induce production of superoxide anion (O2-.) in the adipose 
tissue arteriole. Superoxide anion interferes with the availability of nitric oxide (NO) and reduces 
dilator function of microvessels. Altered microvascular responsiveness may provoke hypoxia in 
the expanded adipose tissue, which via hypoxia inducible factor-1α (HIF-1) would exaggerate 
pathological changes in adipokine production. Adipocytes may also enhance monocyte 
chemotactic protein-1 (MCP-1) synthesis, which facilitates macrophage (mΦ) accumulation and 
activation, to maintain oxidative stress and adipose tissue inflammation. The adipose tissue 
renin-angiotensin-system (RAS) could be one of the sources of increased local production 
angiotensin II, which may contribute to the development of microvascular dysfunction in 
obesity. Evidence indicates that statins, angiotensin converting enzyme inhibitors (ACEI) and 
neutral endopeptidase inhibitors (NEPI) may be effective in restoring arteriolar dilator function 
in obesity. Whether they affect adipose tissue arterioles and whether their direct effects are via 
interfering with altered adipocyte signaling has yet to be elucidated. 
 
 



